Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The 'Task Force on Catastrophic Antiphospholipid Syndrome (CAPS)' was developed on the occasion of the 14th International Congress on Antiphospholipid Antibodies. The objectives of this Task Force were to assess the current knowledge on pathogenesis, clinical and laboratory features, diagnosis and classification, precipitating factors and treatment of this condition in order to address recommendations for future research. This article summarizes the studies analyzed by the Task Force, its recommendations and the future research agenda.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2014.03.002DOI Listing

Publication Analysis

Top Keywords

task force
12
14th international
8
international congress
8
congress antiphospholipid
8
antiphospholipid antibodies
8
catastrophic antiphospholipid
8
antiphospholipid syndrome
8
recommendations future
8
antiphospholipid
4
antibodies task
4

Similar Publications

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best Pract Res Clin Haematol

September 2025

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA; Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, USA.

Immunotherapy, including immune checkpoint blockade, CART cells and bispecific antibodies have resulted in dramatic improvements in outcomes for patients with hematological malignancies, demonstrating the unique potency of the immune system in targeting malignant cells. The development of cancer vaccines aims to evoke an activated effector cell population and a memory response to provide long term immune surveillance to protect from relapse. Developing a potent cancer vaccine relies on identifying appropriate antigen targets, enhancing antigen presentation, and overcoming the immune suppressive milieu of the micro-environment.

View Article and Find Full Text PDF

Future-Proofing European Pharmaceutical Regulatory and Market Access Practices Based on EU Learnings from the COVID-19 Pandemic: Insights from Multi-Stakeholder Interviews.

Ther Innov Regul Sci

September 2025

Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Introduction: During the COVID-19 pandemic, regulatory and market access actions were taken to expedite the market entry of COVID-19 medicines. This study aims to (i) capture multi-stakeholder views on these actions, and (ii) provide recommendations for future-proofing routine and health-emergency frameworks.

Methods: Semi-structured interviews were conducted with policy makers/advisors (i.

View Article and Find Full Text PDF

Objectives: Establishing paediatric DRLs is challenging due to sparse data availability. The objective was to assess paediatric fluoroscopic dose levels in Dutch clinical practice, as current diagnostic reference levels (DRLs) need updating following the European Guidelines on DRLs for Paediatric Imaging (PiDRL).

Material And Methods: Air Kerma-area Product (KAP) values were retrospectively collected from paediatric patients (0-18 years) who underwent fluoroscopic procedures in nine Dutch hospitals between 01-01-2017 and 01-06-2021.

View Article and Find Full Text PDF

Purpose: Urinary toxicity following radical prostatectomy (RP) and postoperative radiotherapy (RT) includes urinary incontinence and vesicourethral anastomosis (VUA) strictures. With the increasing use of stereotactic body radiotherapy (SBRT), dose-escalation, and reirradiation within the prostate bed (PB), standardization of the definition of urinary organs at risk (OARs) in the post-RP setting is needed. This works aims to provide a comprehensive review of the anatomical and physiopathological changes occurring after RP, as well as to provide a consensus on urinary OARs delineation for prostate cancer (PCa) EBRT in the post-RP setting.

View Article and Find Full Text PDF

A carbohydrate placebo (CHO-PLA) is a non-metabolic substance guised as carbohydrate. When information about the treatment was not disclosed, CHO-PLA enhanced strength performance through the sweetness cue, which psychologically strengthened participants' belief in its efficacy. However, the effects of CHO-PLA when participants are misinformed that they are consuming actual carbohydrates, and the role of additional cues (visual reinforcement), remain less understood.

View Article and Find Full Text PDF